相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
Christina Brzezniak et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
Yunguang Sun et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2013)
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
Francesca Casaluce et al.
TARGETED ONCOLOGY (2013)
Antiangiogenic agents in the management of non-small cell lung cancer Where do we stand now and where are we headed?
Charu Aggarwal et al.
CANCER BIOLOGY & THERAPY (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Treating ALK-positive lung cancer-early successes and future challenges
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Jianjun Gao et al.
PHARMACOLOGICAL RESEARCH (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Christine M. Lovly et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas
Zunyan Dai et al.
MOLECULAR CYTOGENETICS (2012)
Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors
Aarif Ahsan et al.
NEOPLASIA (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Avaniyapuram Kannan Murugan et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
Takayuki Kosaka et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Protein kinases: evolution of dynamic regulatory proteins
Susan S. Taylor et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Govardhanan Nagaiah et al.
JOURNAL OF ONCOLOGY (2011)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Roberto T. Bossi et al.
BIOCHEMISTRY (2010)
Defining the conserved internal architecture of a protein kinase
Alexandr P. Kornev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Through the Gatekeeper Door: Exploiting the Active Kinase Conformation
Fabio Zuccotto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
Xiangdong Liu et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Anaplastic lymphoma kinase: signalling in development and disease
Ruth H. Palmer et al.
BIOCHEMICAL JOURNAL (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening-A Report From the American Society of Clinical Oncology
Eric Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
Eva Lin et al.
MOLECULAR CANCER RESEARCH (2009)
Emerging ethnic differences in lung cancer therapy
I. Sekine et al.
BRITISH JOURNAL OF CANCER (2008)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
Xiao-Li Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Robert Roskoski
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin
C Moog-Lutz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
The emerging normal and disease-related roles of anaplastic lymphoma kinase
K Pulford et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
A Motegi et al.
JOURNAL OF CELL SCIENCE (2004)
Protein tyrosine phosphatases in the human genome
A Alonso et al.
CELL (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types
GE Stoica et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The conformational plasticity of protein kinases
M Huse et al.
CELL (2002)
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
GE Stoica et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo
XH Xin et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
MF Di Renzo et al.
ONCOGENE (2000)
分享论文
